{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:39:15Z","timestamp":1790746755931,"version":"4.1.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Ruxolitinib, a Janus kinase (JAK)1\/JAK2 inhibitor, is the standard of care for symptomatic patients with myelofibrosis (MF). However, \u223c70% of patients discontinue ruxolitinib after \u223c5 years, a third of whom report suboptimal splenic response. ADORE was a phase 1b\/2 study with an innovative open platform design that assessed the safety, efficacy, and pharmacokinetics of novel compounds in combination with ruxolitinib in patients with MF who had a suboptimal response to ruxolitinib alone. A total of 44 patients were enrolled in part 1 of the study of ruxolitinib in combination with siremadlin, rineterkib, sabatolimab, crizanlizumab, or NIS793. Most patients were allocated to receive ruxolitinib plus siremadlin (N = 23). The most frequent adverse events with siremadlin were gastrointestinal (nausea and diarrhea) and hematological (thrombocytopenia, anemia, and neutropenia). Siremadlin 30 mg orally once daily on days 1 to 5 of a 28-day cycle was selected as the recommended phase 2 dose. The most robust spleen volume reduction (SVR) at 24 weeks was observed with ruxolitinib plus siremadlin 30 mg. Reductions in percent JAK2V617F allele burden at week 24 were observed, notably in several patients with SVR. An increase in growth differentiation factor 15 protein levels in patients receiving siremadlin demonstrated the on-target modulation of downstream p53 targets. Overall, available data from ADORE suggest the feasibility and benefits of combining novel agents with ruxolitinib in patients with suboptimal response to ruxolitinib alone. This trial was registered at www.clinicaltrials.gov as #NCT04097821.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025015860","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T15:02:22Z","timestamp":1746630142000},"page":"4195-4205","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-2935","authenticated-orcid":false,"given":"David M.","family":"Ross","sequence":"first","affiliation":[{"name":"1Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-1955","authenticated-orcid":false,"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[{"name":"2Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"},{"name":"3Klinik und Poliklinik f\u00fcr Innere Medizin C, Universit\u00e4tsklinikum Greifswald, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-7093","authenticated-orcid":false,"given":"Andrew Charles","family":"Perkins","sequence":"additional","affiliation":[{"name":"4Australian Centre for Blood Diseases, Monash University and Alfred Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-6507","authenticated-orcid":false,"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Crodel","sequence":"additional","affiliation":[{"name":"6Klinik f\u00fcr Innere Medizin II Abt. H\u00e4matologie und Onkologie, Universit\u00e4tsklinikum Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1431-086X","authenticated-orcid":false,"given":"Caroline","family":"Riley","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0505-5126","authenticated-orcid":false,"given":"Mar\u00eda Teresa","family":"G\u00f3mez-Casares","sequence":"additional","affiliation":[{"name":"8Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-4833","authenticated-orcid":false,"given":"Istvan","family":"Takacs","sequence":"additional","affiliation":[{"name":"9Clinic of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6919-4048","authenticated-orcid":false,"given":"Heiko","family":"Becker","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5750-6876","authenticated-orcid":false,"given":"Thomas","family":"Lehmann","sequence":"additional","affiliation":[{"name":"11Clinic for Medical Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3669-0141","authenticated-orcid":false,"given":"Olga","family":"Vinogradova","sequence":"additional","affiliation":[{"name":"12Moscow City Hematology Centre, Botkin Hospital, Moscow, Russia"},{"name":"13Dmitry Rogachev National Research Center of Pediatric Hematology\/Oncology and Immunology, Moscow, Russia"},{"name":"14Pirogov Russian National Research Medical University, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Burbury","sequence":"additional","affiliation":[{"name":"15Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"16Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"17Department of Medicine, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Wondergem","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Amsterdam University Medical Centers, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-438X","authenticated-orcid":false,"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[{"name":"19Department of Hematology, H\u00f4pital Saint-Louis and Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Cleary","sequence":"additional","affiliation":[{"name":"20Novartis Ireland Limited, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Zhang","sequence":"additional","affiliation":[{"name":"21Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagannath","family":"Kota","sequence":"additional","affiliation":[{"name":"22Novartis Healthcare Pvt Ltd, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirudh","family":"Prahallad","sequence":"additional","affiliation":[{"name":"21Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Wroclawska","sequence":"additional","affiliation":[{"name":"21Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4191-4787","authenticated-orcid":false,"given":"Min","family":"Lu","sequence":"additional","affiliation":[{"name":"23Division of Hematology\/Medical Oncology\/Pathology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[{"name":"24Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"issue":"1","key":"2025082608265025500_bib1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-023-01471-z","article-title":"Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety","volume":"16","author":"Verstovsek","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2025082608265025500_bib2","doi-asserted-by":"crossref","first-page":"212603","DOI":"10.7573\/dic.212603","article-title":"Standard care and investigational drugs in the treatment of myelofibrosis","volume":"8","author":"Barraco","year":"2019","journal-title":"Drugs Context"},{"issue":"6","key":"2025082608265025500_bib3","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/10428194.2023.2196593","article-title":"Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy","volume":"64","author":"Pemmaraju","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025082608265025500_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2025082608265025500_bib5","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2025082608265025500_bib6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"2025082608265025500_bib7","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis [published correction appears in Leukemia. 2017;31(3):775]","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2025082608265025500_bib8","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"2025082608265025500_bib9","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann Hematol"},{"issue":"21","key":"2025082608265025500_bib10","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood.V122.21.2833.2833","article-title":"Ruxolitinib discontinuation in patients with myelofibrosis: an analysis from clinical practice","volume":"122","author":"Fonseca","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2025082608265025500_bib11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"issue":"4","key":"2025082608265025500_bib12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/hon.2898","article-title":"Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-intermediate-1-intermediate-2-and high-risk myelofibrosis in JUMP, a phase 3b, expanded-access study","volume":"39","author":"Passamonti","year":"2021","journal-title":"Hematol Oncol"},{"issue":"2","key":"2025082608265025500_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.beha.2014.07.009","article-title":"Rationale for combination therapy in myelofibrosis","volume":"27","author":"Mascarenhas","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"issue":"15","key":"2025082608265025500_bib14","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J Clin Oncol"},{"issue":"32","key":"2025082608265025500_bib15","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naive myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025082608265025500_bib16","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2352-3026(22)00116-8","article-title":"Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study","volume":"9","author":"Pemmaraju","year":"2022","journal-title":"Lancet Haematol"},{"issue":"16","key":"2025082608265025500_bib17","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-04-846626","article-title":"A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis","volume":"132","author":"Masarova","year":"2018","journal-title":"Blood"},{"issue":"18","key":"2025082608265025500_bib18","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1182\/bloodadvances.2023010628","article-title":"Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis","volume":"7","author":"Gupta","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2025082608265025500_bib19","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-alpha2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"S\u00f8rensen","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"2025082608265025500_bib20","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1078-0432.CCR-21-1295","article-title":"Results from a first-in-human phase I study of siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia","volume":"28","author":"Stein","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2025082608265025500_bib21","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.1158\/0008-5472.CAN-18-0338","article-title":"Dose and schedule determine distinct molecular mechanisms underlying the efficacy of the p53-MDM2 inhibitor HDM201","volume":"78","author":"Jeay","year":"2018","journal-title":"Cancer Res"},{"issue":"suppl 15","key":"2025082608265025500_bib22","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1200\/JCO.2020.38.15_suppl.3640","article-title":"Phase I dose-finding study of oral ERK1\/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations","volume":"38","author":"Janku","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7836","key":"2025082608265025500_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-020-2968-3","article-title":"Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms","volume":"588","author":"Jayavelu","year":"2020","journal-title":"Nature"},{"issue":"5","key":"2025082608265025500_bib24","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/ajh.26889","article-title":"Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms","volume":"98","author":"Ivanov","year":"2023","journal-title":"Am J Hematol"},{"issue":"11","key":"2025082608265025500_bib25","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/nm.3364","article-title":"Differential regulation of myeloid leukemias by the bone marrow microenvironment","volume":"19","author":"Krause","year":"2013","journal-title":"Nat Med"},{"issue":"2","key":"2025082608265025500_bib26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41375-020-0880-3","article-title":"Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice","volume":"35","author":"Ozono","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"2025082608265025500_bib27","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood.2019003276","article-title":"Megakaryocyte TGF\u03b21 partitions erythropoiesis into immature progenitor\/stem cells and maturing precursors","volume":"136","author":"Di Giandomenico","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2025082608265025500_bib28","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9","article-title":"Cancer phase I clinical trials: efficient dose escalation with overdose control","volume":"17","author":"Babb","year":"1998","journal-title":"Stat Med"},{"issue":"13","key":"2025082608265025500_bib29","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/sim.3230","article-title":"Critical aspects of the Bayesian approach to phase I cancer trials","volume":"27","author":"Neuenschwander","year":"2008","journal-title":"Stat Med"},{"issue":"5","key":"2025082608265025500_bib30","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study","volume":"5","author":"Luque Paz","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"2025082608265025500_bib31","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2025082608265025500_bib32","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"2025082608265025500_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"key":"2025082608265025500_bib34","doi-asserted-by":"crossref","first-page":"106222","DOI":"10.1016\/j.leukres.2019.106222","article-title":"Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: a systematic review of the literature","volume":"86","author":"Pi","year":"2019","journal-title":"Leuk Res"},{"issue":"22","key":"2025082608265025500_bib35","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood.V128.22.593.593","article-title":"Phase 1 dose escalation study of MDM2 inhibitor DS-3032b in patients with hematological malignancies - preliminary results","volume":"128","author":"DiNardo","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2025082608265025500_bib36","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2018893545","article-title":"Oral idasanutlin in patients with polycythemia vera","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood"},{"issue":"13","key":"2025082608265025500_bib37","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1182\/bloodadvances.2019030916","article-title":"Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed\/refractory acute myeloid leukemia","volume":"3","author":"Erba","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"2025082608265025500_bib38","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2025082608265025500_bib39","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(22)00102-8","article-title":"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","volume":"9","author":"Passamonti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"19","key":"2025082608265025500_bib40","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"2025082608265025500_bib41","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.1182\/bloodadvances.2020002379","article-title":"Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin","volume":"4","author":"Marcellino","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2025082608265025500_bib42","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","article-title":"Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution","volume":"55","author":"Rodriguez-Meira","year":"2023","journal-title":"Nat Genet"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4195\/2407218\/blooda_adv-2025-015860-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4195\/2407218\/blooda_adv-2025-015860-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T12:27:08Z","timestamp":1756211228000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/16\/4195\/537150\/ADORE-an-open-platform-study-of-ruxolitinib-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":42,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,8,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015860","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,26]]},"published":{"date-parts":[[2025,8,15]]}}}